These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33674403)

  • 1. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim
    Zwezerijnen GJC; Eertink JJ; Burggraaff CN; Wiegers SE; Shaban EAIN; Pieplenbosch S; Oprea-Lager DE; Lugtenburg PJ; Hoekstra OS; de Vet HCW; Zijlstra JM; Boellaard R
    J Nucl Med; 2021 Nov; 62(11):1531-1536. PubMed ID: 33674403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.
    Barrington SF; Zwezerijnen BGJC; de Vet HCW; Heymans MW; Mikhaeel NG; Burggraaff CN; Eertink JJ; Pike LC; Hoekstra OS; Zijlstra JM; Boellaard R
    J Nucl Med; 2021 Mar; 62(3):332-337. PubMed ID: 32680929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in
    Driessen J; Zwezerijnen GJC; Schöder H; Drees EEE; Kersten MJ; Moskowitz AJ; Moskowitz CH; Eertink JJ; Vet HCW; Hoekstra OS; Zijlstra JM; Boellaard R
    J Nucl Med; 2022 Sep; 63(9):1424-1430. PubMed ID: 34992152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma.
    Burggraaff CN; Rahman F; Kaßner I; Pieplenbosch S; Barrington SF; Jauw YWS; Zwezerijnen GJC; Müller S; Hoekstra OS; Zijlstra JM; De Vet HCW; Boellaard R;
    Mol Imaging Biol; 2020 Aug; 22(4):1102-1110. PubMed ID: 31993925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
    Eertink JJ; Pfaehler EAG; Wiegers SE; van T; Brug D; Lugtenburg PJ; Hoekstra OS; Zijlstra JM; de Vet HCW; Boellaard R
    J Nucl Med; 2022 Mar; 63(3):389-395. PubMed ID: 34272315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combatting the effect of image reconstruction settings on lymphoma [
    Ferrández MC; Eertink JJ; Golla SSV; Wiegers SE; Zwezerijnen GJC; Pieplenbosch S; Zijlstra JM; Boellaard R
    EJNMMI Res; 2022 Jul; 12(1):44. PubMed ID: 35904645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 10. A new method for segmentation of FDG PET metabolic tumour volume using the peritumoural halo layer and a 10-step colour scale. A study in patients with papillary thyroid carcinoma.
    Jun S; Kim H; Nam HY
    Nuklearmedizin; 2015; 54(6):272-85. PubMed ID: 26429587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interobserver Agreement of Interim and End-of-Treatment
    Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
    J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
    Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
    Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic parameters on baseline and interim [ 18 F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients.
    Czibor S; Carr R; Redondo F; Auewarakul CU; Cerci JJ; Paez D; Fanti S; Györke T
    Nucl Med Commun; 2023 Apr; 44(4):291-301. PubMed ID: 36705233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
    Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
    Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
    Gupta N; Singh N
    Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of
    Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
    J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.
    Benz MR; Evilevitch V; Allen-Auerbach MS; Eilber FC; Phelps ME; Czernin J; Weber WA
    J Nucl Med; 2008 Jul; 49(7):1038-46. PubMed ID: 18552153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline
    Boellaard R; Buvat I; Nioche C; Ceriani L; Cottereau AS; Guerra L; Hicks RJ; Kanoun S; Kobe C; Loft A; Schöder H; Versari A; Voltin CA; Zwezerijnen GJC; Zijlstra JM; Mikhaeel NG; Gallamini A; El-Galaly TC; Hanoun C; Chauvie S; Ricci R; Zucca E; Meignan M; Barrington SF
    J Nucl Med; 2024 Sep; 65(9):1343-1348. PubMed ID: 39089812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Parameters of
    Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
    Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.